SPARCL


Also found in: Acronyms.

SPARCL

Neurology A clinical trial–Stroke Prevention by Aggressive Reduction in Cholesterol Levels
Mentioned in ?
References in periodicals archive ?
These results should be viewed as exploratory" because the SPARCL trial was not powered to test for subgroup effects, they noted.
SPARCL is an investigator-led trial that is being coordinated by an independent
In SPARCL, 4,731 patients who had no history of heart disease and had
An analysis of the SPARCL data was designed and conducted after the study ended to explore the types of strokes, ischemic or hemorrhagic, that occurred among patients in the study.
In SPARCL, 4,731 patients who had no history of heart disease and had experienced a stroke or TIA within six months prior to trial enrollment were followed for an average of about five years.
In this new post-hoc analysis (planned after the study closed) of the SPARCL study, kidney function was evaluated by estimated glomerular filtration rate (eGFR, mL/min/1.
In the SPARCL study, patients with chronic kidney disease had higher risk of stroke (27 percent) or major coronary events (70 percent) compared to patients without chronic kidney disease.
The SPARCL study, published in the New England Journal of Medicine in 2006, is the only study to date evaluating statin therapy exclusively for patients with recent stroke or mini-stroke and no coronary heart disease (n=4,731).
The benefits of Lipitor 80 mg in patients with a recurrent stroke or mini-stroke seen in this analysis are consistent with the primary SPARCL results which demonstrated the benefit of Lipitor 80 mg in reducing stroke and coronary events among all patients in the study (n=4,731).
The authors suggest that future guidelines for lipid management may require additional revision to reflect the results of newer trials such as SPARCL that support the use of statins in stroke patients without coronary heart disease.
SPARCL revealed that the drug Lipitor, given in high doses to stroke patients who had no heart disease, was effective in preventing a second stroke and first heart attack.
The SPARCL study enrolled 4,731 patients who had no history of heart disease and had experienced a stroke or TIA (mini-stroke) within six months prior to trial enrollment.